北京利德曼生化股份有限公司（以下简称“利德曼”）重大资产购买事项近日获得独立财务顾问中信建投证券股份有限公司（以下简称“中信建投”）的核查确认。针对深圳证券交易所此前下发的重组问询函，中信建投就交易资金来源、标的公司业绩预测、评估方法、资产剥离等核心问题进行了详细回复，认为本次交易定价公允，资金安排合理，不会对上市公司日常经营产生重大不利影响。根据公告，利德曼拟以现金方式收购先声祥瑞生物制品股份...
Source Link北京利德曼生化股份有限公司（以下简称“利德曼”）重大资产购买事项近日获得独立财务顾问中信建投证券股份有限公司（以下简称“中信建投”）的核查确认。针对深圳证券交易所此前下发的重组问询函，中信建投就交易资金来源、标的公司业绩预测、评估方法、资产剥离等核心问题进行了详细回复，认为本次交易定价公允，资金安排合理，不会对上市公司日常经营产生重大不利影响。根据公告，利德曼拟以现金方式收购先声祥瑞生物制品股份...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.